(Image: Associated Press)
Novartis scores its latest FDA OK — this time for a new sickle cell disease drug picked up in a $665M deal
Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
